Zhejiang Huahai Pharmaceutical Co Ltd Market Cap ($3.67 Billion)
Market Cap & Net Worth: Zhejiang Huahai Pharmaceutical Co Ltd (600521)
Zhejiang Huahai Pharmaceutical Co Ltd market cap. Zhejiang Huahai Pharmaceutical Co Ltd (SHG:600521) has a market capitalization of $3.67 Billion (CN¥25.05 Billion) as of October 27, 2026. Listed on the SHG stock exchange, this China-based company holds position #4239 globally and #613 in its home market, demonstrating a 1.33% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Zhejiang Huahai Pharmaceutical Co Ltd's stock price CN¥16.73 by its total outstanding shares 1497252196 (1.50 Billion).
Zhejiang Huahai Pharmaceutical Co Ltd Market Cap History (2015–2026)
Zhejiang Huahai Pharmaceutical Co Ltd market cap history from 2015 to 2026. Data shows growth from $3.06 Billion to $3.67 Billion (2.02% CAGR). Check today's stock price for Zhejiang Huahai Pharmaceutical Co Ltd for real-time trading data and today's change.
Zhejiang Huahai Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Zhejiang Huahai Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see Zhejiang Huahai Pharmaceutical Co Ltd operating cash flow efficiency for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
0.43x
Zhejiang Huahai Pharmaceutical Co Ltd's market cap is 0.43 times its annual revenue
Latest Price to Earnings (P/E) Ratio
13.96x
Zhejiang Huahai Pharmaceutical Co Ltd's market cap is 13.96 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $3.48 Billion | $4.09 Billion | $500.83 Million | 0.85x | 6.95x |
| 2017 | $4.80 Billion | $5.00 Billion | $639.25 Million | 0.96x | 7.51x |
| 2018 | $2.13 Billion | $5.09 Billion | $107.51 Million | 0.42x | 19.80x |
| 2019 | $3.32 Billion | $5.39 Billion | $569.60 Million | 0.62x | 5.83x |
| 2020 | $7.21 Billion | $6.49 Billion | $929.82 Million | 1.11x | 7.75x |
| 2021 | $4.66 Billion | $6.64 Billion | $487.54 Million | 0.70x | 9.56x |
| 2022 | $4.73 Billion | $8.27 Billion | $1.17 Billion | 0.57x | 4.05x |
| 2023 | $3.21 Billion | $8.31 Billion | $830.47 Million | 0.39x | 3.87x |
| 2024 | $3.92 Billion | $9.55 Billion | $1.12 Billion | 0.41x | 3.50x |
| 2025 | $3.72 Billion | $8.59 Billion | $266.40 Million | 0.43x | 13.96x |
Competitor Companies of 600521 by Market Capitalization
Companies near Zhejiang Huahai Pharmaceutical Co Ltd in the global market cap rankings as of October 27, 2026. See Zhejiang Huahai Pharmaceutical Co Ltd net asset quality index to understand what proportion of total assets are financed by equity.
Key companies related to Zhejiang Huahai Pharmaceutical Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #517 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #539 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #615 globally with a market cap of $43.87 Billion USD ( CN¥299.81 Billion CNY).
- Haleon plc (NYSE:HLN): Ranked #619 globally with a market cap of $43.73 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #517 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #539 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $46.10 |
| #615 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $43.87 Billion | CN¥47.00 |
| #619 | Haleon plc | NYSE:HLN | $43.73 Billion | $10.20 |
Market Capitalization of Zhejiang Huahai Pharmaceutical Co Ltd (2015–2026)
Market capitalization of Zhejiang Huahai Pharmaceutical Co Ltd from 2015 to today. Between 2015 and today, Zhejiang Huahai Pharmaceutical Co Ltd's market cap moved from $3.06 Billion to $ 3.67 Billion, with a yearly change of 2.02%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥3.67 Billion | -1.41% |
| 2025 | CN¥3.72 Billion | -5.04% |
| 2024 | CN¥3.92 Billion | +21.81% |
| 2023 | CN¥3.21 Billion | -32.00% |
| 2022 | CN¥4.73 Billion | +1.39% |
| 2021 | CN¥4.66 Billion | -35.32% |
| 2020 | CN¥7.21 Billion | +117.00% |
| 2019 | CN¥3.32 Billion | +56.06% |
| 2018 | CN¥2.13 Billion | -55.65% |
| 2017 | CN¥4.80 Billion | +37.96% |
| 2016 | CN¥3.48 Billion | +13.72% |
| 2015 | CN¥3.06 Billion | -- |
End of Day Market Cap According to Different Sources
On Oct 27th, 2026 the market cap of Zhejiang Huahai Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.67 Billion USD |
| MoneyControl | $3.67 Billion USD |
| MarketWatch | $3.67 Billion USD |
| marketcap.company | $3.67 Billion USD |
| Reuters | $3.67 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Zhejiang Huahai Pharmaceutical Co Ltd
Zhejiang Huahai Pharmaceutical Co., Ltd. engaged in the research, development, production, and sales of generic drugs, biologics, drugs, and specialty active pharmaceutical ingredients in multiple dosage forms in China and internationally. The company offers central neurological, cardiovascular, anti-viral, and other products, as well as APIs and intermediates. It also provides packaging componen… Read more